Reviewing Neptune Wellness Solutions Inc. (NEPT)’s and Osmotica Pharmaceuticals plc (NASDAQ:OSMT)’s results

Neptune Wellness Solutions Inc. (NASDAQ:NEPT) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neptune Wellness Solutions Inc. 3 0.00 64.59M 0.00 0.00
Osmotica Pharmaceuticals plc 5 0.00 7.33M -4.57 0.00

Table 1 highlights Neptune Wellness Solutions Inc. and Osmotica Pharmaceuticals plc’s gross revenue, earnings per share (EPS) and valuation.


Table 2 has Neptune Wellness Solutions Inc. and Osmotica Pharmaceuticals plc’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Neptune Wellness Solutions Inc. 2,046,577,946.77% 0% 0%
Osmotica Pharmaceuticals plc 153,991,596.64% 0% 0%

Analyst Recommendations

The Recommendations and Ratings for Neptune Wellness Solutions Inc. and Osmotica Pharmaceuticals plc are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neptune Wellness Solutions Inc. 0 0 1 3.00
Osmotica Pharmaceuticals plc 0 0 0 0.00

Neptune Wellness Solutions Inc. has a consensus price target of $10, and a 261.01% upside potential.

Insider and Institutional Ownership

Roughly 17.35% of Neptune Wellness Solutions Inc. shares are held by institutional investors while 50.4% of Osmotica Pharmaceuticals plc are owned by institutional investors. Insiders held roughly 18.84% of Neptune Wellness Solutions Inc.’s shares. Competitively, Osmotica Pharmaceuticals plc has 4% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neptune Wellness Solutions Inc. -7.14% 32.41% 38.16% 73.86% 100.7% 125.2%
Osmotica Pharmaceuticals plc -1.51% -16.2% -17.47% -59.15% 0% -57.94%

For the past year Neptune Wellness Solutions Inc. has 125.2% stronger performance while Osmotica Pharmaceuticals plc has -57.94% weaker performance.


Neptune Wellness Solutions Inc. beats on 6 of the 8 factors Osmotica Pharmaceuticals plc.

Neptune Technologies & Bioressources Inc., a nutrition products company, focuses on providing nutrition solutions, including specialty ingredients and consumer brands. The company develops solutions available in various delivery forms. It also offers various specialty ingredients, including premium krill oil and other marine oils, as well as seed oils. The company sells its premium krill oil under the OCEANO3 brand directly to consumers through in Canada and the United States. In addition, Neptune Technologies & Bioressources Inc. is pursuing opportunities in the prescription drug markets, through its subsidiary, Acasti Pharma Inc., that focuses on the research, development, and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. The company was founded in 1925 and is headquartered in Laval, Canada.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.